Posted on 04/18/2025 3:29:42 PM PDT by nickcarraway
The Defender’s Big Pharma Watch delivers the latest headlines related to pharmaceutical companies and their products, including vaccines, drugs, and medical devices and treatments. The views expressed in the below excerpts from other news sources do not necessarily reflect the views of The Defender. Our goal is to provide readers with breaking news that affects human health and the environment.
Idaho Capital Sun reported:
Idaho Gov. Brad Little signed into law a bill to let ivermectin be sold as an over-the-counter medicine — without a prescription or consultation with a health care professional. Typically used to treat parasites in humans, ivermectin has drawn interest since the COVID-19 pandemic — after largely conservative activists, doctors and politicians inaccurately touted it as an alternative medicine.
Usually, the U.S. Food and Drug and Administration, or FDA, handles whether drugs should be made available over-the-counter, a process that uses data on safety and effectiveness. The FDA hasn’t approved ivermectin to treat or prevent COVID-19, saying the federal agency finds existing clinical trial data don’t show “ivermectin is effective against COVID-19 in humans.” The federal regulator’s website also warns large doses of ivermectin “can be dangerous,” overdose can risk death, and human-appropriate doses can interact with other medications, such as blood thinners.
Little on Monday signed Senate Bill 1211, the ivermectin deregulation bill, according to the governor office’s legislation tracker. The new law takes effect immediately — through an emergency clause. Passed during the last week of this year’s legislative session, Idaho lawmakers didn’t hear public feedback on the bill from doctors, pharmacists or health care professionals.
Vaccine Panel Urges More Protection Against RSV, Meningitis and Chikungunya U.S. News & World Report reported:
A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including respiratory syncytial virus (RSV), meningitis and a mosquito-borne illness called chikungunya.
The panel, known as the Advisory Committee on Immunization Practices, makes vaccine use recommendations to the director of the U.S. Centers for Disease Control and Prevention (CDC), The Associated Press reported. These recommendations are almost always approved. But recent leadership changes at the CDC may complicate next steps.
The new recommendations include:
Adults aged 50 to 59 with certain health problems, like heart disease, diabetes or chronic obstructive pulmonary disorder should be able to get the RSV shot. A new combination vaccine from GSK was endorsed. It protects against five types of meningococcal bacteria, including one linked to college campus outbreaks about 10 years ago. Moderna Advances Pandemic Preparedness Agenda With UK Clearance for Commercial mRNA Vaccine Plant Fierce Pharma reported:
Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key regulatory hurdle at its flagship production plant in the U.K. The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted Moderna a manufacturer and importer’s license at its vaccine facility in Harwell, Oxfordshire.
With license in hand and the plant now fully operational, Moderna is free to use the site for commercial production of mRNA shots, which will then be beholden to MHRA’s standard review process, the company said in an April 15 press release.
The facility, dubbed the Moderna Innovation and Technology Centre, forms a major component of the company’s 10-year partnership with the U.K. government and its Health Security Agency to prepare for future pandemics. The pact is designed to shore up domestic vaccine production in the U.K., bolster the country’s R&D prowess and ensure “priority access” to mRNA vaccines in the event of an emergency, Moderna noted in its release.
CDC’s Broader RSV Recommendation Could Be Boon for GSK, Pfizer FirstWord Pharma reported:
After revenues for GSK and Pfizer’s respective respiratory syncytial virus (RSV) vaccines took a hit last year, a new recommendation from the U.S. Centers for Disease Control and Prevention (CDC) could help them gain back some ground.
The meeting of the CDC’s Advisory Committee on Immunization Practices (ACIP) took place this week after a nearly two-month delay. Originally scheduled for late February, the panel was postponed shortly after Robert F. Kennedy Jr. was sworn in as Health and Human Services (HHS) Secretary.
On Wednesday, ACIP voted to widen its recommendation on who should receive an RSV jab to include adults ages 50 to 59 who are at an increased risk of severe RSV disease. Pfizer’s Abrysvo and GSK’s Arexvy, both of which already have FDA approval in that patient population, stand to benefit from the expanded recommendation.
Last year, ACIP released a narrow vaccination recommendation that only applied to individuals 75 and older, as well as high-risk adults between the ages of 60 and 74 — a limited scope compared with the committee’s broader 2023 policy, under which all adults over the age of 60 “may receive” an RSV jab following discussions with their healthcare provider.
GSK Scolded After Complainant Flags ‘Shocking Error’ in Prescribing Information Fierce Pharma reported:
GSK has been found guilty of bringing discredit on the pharma industry after a complainant flagged “a shocking error” in the prescribing information for the JAK inhibitor Omjjara.
A person who self-identified as a health professional wrote to the PMCPA, the body that oversees the U.K. marketing code, after finding fault with prescribing information for Omjjara. The drug is contraindicated in pregnancy, and the line that startled the complainant says, “Women using oral hormonal contraceptives should add a barrier method during treatment and for at least 1 week after the last dose of Omjjara.”
According to the complainant, “common sense and reasoning suggests any non-oral hormone contraception will raise the same concern,” leading them to “query the ability of GSK to accurately produce prescribing information and query whether sufficient checks have been made to these items prior to release.”
without a prescription?
Hello. You had a list before of sources where to buy Ivermectin without a prescription. Just wondering if you have that info. Thanks
that’s what I did during covid. I remember a Freeper instructing me on the forum, how much I should add to my bagel Lol. I need to order some..
Don’t need one. It is horse paste.
I’ll post the whole pile of links. Bottom link goes to a post with a bunch of sources. I’ve never used any of them. Some links in both posts may be getting stale, might have to use the Wayback Machine.
If you happen to be in TN, Ivermectin is OTC and there’s probably a compounding pharmacy near you that has it. Of course, there’s always good ole Tractor Supply for Durvet apple-flavored horse paste.
Ivermectin links. More than you probably want to know about Ivermectin:
General info on use vs. Covid, etc. https://www.barnhardt.biz/ivermectin/
Huge meta study https://ivmmeta.com/
Doctors using it and protocols https://covid19criticalcare.com/ivermectin-in-covid-19/
https://covid19criticalcare.com/covid-19-protocols/
https://vladimirzelenkomd.com/treatment-protocol/
Emory University has a very prestigious medical school. The Dean of Emory Medical School has Indian heritage, and co-wrote an article in the Times of India advocating using Ivermectin against Covid, among other things. This has gotten =ZERO= coverage in US media, including his hometown paper, the AJC, and his hometown news network, CNN.
Try to convince me that isn’t newsworthy - both his original article and the non-coverage of it by US media.
Link to the article discussed above, and Emory’s leadership page.
Existing affordable drugs could rapidly reduce Covid-19 cases and deaths in India
One of the authors appears below as Dean https://www.med.emory.edu/about/leadership/index.html
Africa and Ivermectin
https://archive.is/2021.08.28-042601/https://threadreaderapp.com/thread/1431339779703017477.html
The infographic there is excellent. Summary: The parts of Africa where Ivermectin is in widespread use to prevent a terrible parasitic disease, African River Blindness, also have very low Covid incidence.
Interesting Twitter account that has linked many Ivermectin and other med studies on Covid treatments. https://twitter.com/Covid19Crusher
Discovery of Ivermectin. A National Historic Chemical Landmark per the American Chemical Society. Not something to be derided as “horse dewormer”. https://www.acs.org/content/dam/acsorg/education/whatischemistry/landmarks/discovery-of-ivermectin-mectizan.pdf.
“The Story of Ivermectin”
https://www.bitchute.com/video/ZqVlyy6YtNiz/
https://rumble.com/vr0rim-the-ivermectin-story-original-and-uncut.html
Good 24 minute summary.
Ivermectin and Cancer https://communities.win/c/Conspiracies/p/12kFnAdfAW/ivermectin-cures-cancer-/
India’s Ivermectin Blackout - Part V: The Secret Revealed https://www.thedesertreview.com/opinion/columnists/indias-ivermectin-blackout-—part-v-the-secret-revealed/article_9a37d9a8-1fb2-11ec-a94b-47343582647b.html
Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations https://www.nature.com/articles/ja201711.pdf
Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects https://www.cureus.com/articles/111851-regular-use-of-ivermectin-as-prophylaxis-for-covid-19-led-up-to-a-92-reduction-in-covid-19-mortality-rate-in-a-dose-response-manner-results-of-a-prospective-observational-study-of-a-strictly-controlled-populatio
Ivermectin, ‘Wonder drug’ from Japan: the human use perspective by Andy CRUMP and Satoshi ŌMURA
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043740/
Dr. Omura was one of the Nobel Prize in Medicine winners for discovering Ivermectin. Article is at NIH, and is from the Proceedings of the Japan Academy, a prestigious medical publication.
Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations https://www.nature.com/articles/ja201711
Nice Dr. Omura meme: https://patriots.win/p/15JmxJouZN/dr-satoshi-omura-/c/
PLACES TO BUY GENERIC MEDS (Unvetted)
https://patriots.win/p/17tKirX7aK/places-to-buy-generic-meds—anti/
Oops, it was at the bottom of post 8, same bunch of links. Sorry for the repost, all.
I have had good results with valleyvet.com, $8.99 per tube.
... that’s what I did during covid. I remember a Freeper instructing me on the forum, how much I should add to my bagel...
Interesting....during ChyNah virus, eh?
Yet your FR birth date is TODAY.
Welcome to FR, again.
What was your previous name? 🧐
Also ... how do you post so many posts, at the exact same time?
Ping!
🦗 🦗 🦗 {chiirrrp, chiirrrp, chiirrrp…}
Oh, neocon ... where did you run off to? 🕵️
Thank you for that info!!
Greatly appreciated ;^)
"Oh, neocon ... where did you run off to?"
patriots win link is great.
The Grantpharmacy site, I communicated with them and they are in India. I would think IV pills will come stateside..
same BS, er I mean procedures as 24 years ago, everything is under review when you’re rookie. Not my fault they purged me for no activity in 5 years...
Man, it warms the heart my fanclub remembers me XD
I’m hoping it becomes OTC once RFKJr. gets rolling.
Along with HCQ.
Ah ... a retread :-)
What was your previous FR name?
only available OTC in Idaho, but the state medical board said it is sold “fermented ort compounded, which means once it’s compounded, the drug or medicine cannot be sold OTC.
buncha killjoys..
updating my previous reply: the grantpharmacy seller site, link on your patriotswin link, is based in India. I had to communicate with them if it’s coming stateside.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.